Dechra Pharmaceuticals PLC — Director's Dealing 2021

Sep 17, 2021

National Storage Mechanism | Additional information

RNS Number : 1755M

Dechra Pharmaceuticals PLC

17 September 2021

17 September 2021

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

The Company announces that on 16 September 2021 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive Plan:

Name of individual	Director	Type of award	Number of shares subject to award
Ian Page	Director	LTIP Award - nil cost option	23,727
Paul Sandland*	Director	LTIP Award - nil cost option	11,000
Tony Griffin	Director	LTIP Award - conditional award	6,508

* Paul Sandland has also been granted a tax qualifying option over 330 shares at an exercise price of £49.09 as part of his LTIP award. This tax qualifying option is linked to the nil cost option such that, at the time of exercise, to the extent that there is a gain in the tax qualifying option, the nil cost option will be forfeited to the value of that gain.

The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Forms

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Nil cost option

Price	Volume
Nil cost award	23,727

d)

Aggregated information

-   Aggregate volume

-   Price

N/A

N/A

e)

Date of the transaction

2021-09-16

f)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Nil cost option

Price	Volume
Nil cost award	11,000

Tax qualifying option

Price	Volume
£49.09 (per Ordinary Share exercise price)	330

d)

Aggregated information

-   Aggregate volume

-   Price

Awards granted over 11,330 Ordinary Shares in total

N/A

e)

Date of the transaction

2021-09-16

f)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Conditional award

Price	Volume
Nil cost award	6,508

d)

Aggregated information

-   Aggregate volume

-   Price

N/A

N/A

e)

Date of the transaction

2021-09-16

f)

Place of the transaction

Outside a trading venue

For further information, please contact:

Melanie Hall, Company Secretary                  

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDCISBDGBR